New drug combination as second treatment for advanced colorectal cancer

Plain-English translation of NCT07559760 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new combination chemotherapy approach for people with advanced colorectal cancer that has progressed despite initial treatment. The combination includes levoleucovorin, 5-FU, and liposomal irinotecan, often paired with one of two targeted drugs that your doctor will choose. The goal is to see how well this treatment works and how safe it is for patients like you.

Many people with advanced colorectal cancer stop responding to their first treatment or can't tolerate it. This medication combination represents a newer approach that researchers hope will be more effective and better tolerated than currently available second-line options.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced colorectal cancer that has spread to other parts of your body
your cancer has either stopped responding to or caused intolerable side effects from your first-line chemotherapy treatment
your cancer is MSS-type (a specific genetic classification) and cannot be surgically removed
you are in good enough overall health to tolerate treatment, with expected survival of at least 3 months
your blood counts, kidney function, liver function, and heart function are adequate based on recent blood tests

You likely don't qualify if…

you have ever received a topoisomerase-I inhibitor drug as part of your first treatment
you are allergic to any of the medications being tested in this trial
you are pregnant, breastfeeding, or unwilling to use effective birth control during and after treatment
you have serious heart problems, recent heart attack or stroke, or unstable chest pain
you have had any cancer treatment or major surgery within the past 4 weeks that has not fully healed

What participation looks like

You would visit the study center every 2 weeks to receive the medication combination by IV infusion. The treatment involves an IV infusion given over 90 minutes on day 1, plus a continuous infusion pump that you carry for about 2 days. You may receive up to 12 cycles of the main chemotherapy drug, with the possibility of switching to a maintenance treatment afterward. Throughout the study, you'll have regular blood tests and imaging scans to monitor how your cancer responds and how you're tolerating the treatment.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(1 site)

China

The First Hospital of Jilin University, Changchun, Jilin